# Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

> **NCT00126542** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Primary Peritoneal Cavity Cancer
- Recurrent Ovarian Epithelial Cancer
- Stage IV Ovarian Epithelial Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** erlotinib hydrochloride
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00126542
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2007-01
- **Final completion:** 2010-04
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2014-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126542, "Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00126542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*